Among them, the clinical impact of CYP2D6-dependent metabolism of primaquine should be included to respond whether the Brazilian national malaria control program can establish genetic-based strategies to monitor subpopulations at greater risk for malaria relapse. The gene discussed is CYP2D6; the disease is malaria.